Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

Axillary Web Syndrome (AWS) represents a notable yet often under‐recognised complication arising from breast cancer surgery, including sentinel lymph node dissection and biopsy. Characterised by the ...

Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...

SAN ANTONIO — Women with early breast cancer who have less extensive axillary surgery see no effect on their 10-year rates of locoregional recurrence and mortality than do those who have more ...

Patients with lymph node-positive breast cancer may still avoid extensive axillary surgery if they have clear nodes after systemic therapy, data from a prospective registry showed. Patients with clear ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer The American College of Surgeons Oncology Group Z1071 trial reported a 12.6% ...